Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene

Prostate

Volumn 72, Issue 9, 2012, Pages 991-997

  Fleischmann, A ^a,b   Huland, H ^a   Mirlacher, M ^a   Wilczak, W ^a   Simon, R ^a   Erbersdobler, A ^a   Sauter, G ^a   Schlomm, T ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bcl 2; fluorescence in situ hybridization; prognosis; prostate cancer; tissue microarray

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ABERRATION; CONTROLLED STUDY; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

AGED; DISEASE PROGRESSION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSLOCATION, GENETIC;

EID: 84861101333     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21504     Document Type: Article

References (27)

1. Kirkin V, Joos S, Zornig M,. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644 (2-3): 229-249.
2. Zhivotovsky B, Orrenius S,. Carcinogenesis and apoptosis: Paradigms and paradoxes. Carcinogenesis 2006; 27 (10): 1939-1945.
3. Bubendorf L, Sauter G, Moch H, Jordan P, Blochlinger A, Gasser TC, Mihatsch MJ,. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996; 148 (5): 1557-1565.
4. Catz SD, Johnson JL,. BCL-2 in prostate cancer: A minireview. Apoptosis 2003; 8 (1): 29-37.
5. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T,. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998; 153 (1): 141-148.
6. Erbersdobler A, Fritz H, Schnoger S, Graefen M, Hammerer P, Huland H, Henke RP,. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: Differences between tumours located in the transition zone and in the peripheral zone. Eur Urol 2002; 41 (1): 40-46.
7. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP,. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999; 59 (4): 803-806.
8. Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A,. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008; 21 (11): 1371-1378.
9. Lin Y, Fukuchi J, Hiipakka RA, Kokontis JM, Xiang J,. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. Cell Res 2007; 17 (6): 531-536.
10. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R,. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993; 143 (2): 390-400.
11. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC,. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148 (5): 1567-1576.
12. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML,. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52 (24): 6940-6944.
13. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45.
14. Kallakury BV, Figge J, Leibovich B, Hwang J, Rifkin M, Kaufman R, Figge HL, Nazeer T, Ross JS,. Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8kb major breakpoint region or with p53 protein accumulation. Mod Pathol 1996; 9 (1): 41-47.
15. Augustin H, Hammerer PG, Graefen M, Palisaar J, Daghofer F, Huland H, Erbersdobler A,. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy. J Cancer Res Clin Oncol 2003; 129 (11): 662-668.
16. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW,. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996; 156 (4): 1511-1516.
17. Borre M, Stausbol-Gron B,. Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 2000; 164 (3 Pt 1): 716-721.
18. Bai XZ, Masters JR, O'Donoghue N, Kirby R, Pan LX, Young M, Stafford M, Parkinson MC,. Prognostic markers in clinically localised prostate cancer. Int J Oncol 1999; 14 (4): 785-791.
19. Brewster SF, Oxley JD, Trivella M, Abbott CD, Gillatt DA,. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 1999; 161 (4): 1238-1243.
20. Kaur P, Kallakury BS, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS,. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 2004; 128 (1): 39-43.
21. Keshgegian AA, Johnston E, Cnaan A,. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 1998; 110 (4): 443-449.
22. Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P, Koutsilieris M,. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res 2005; 25 (4): 3123-3133.
23. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr., p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997; 158 (1): 131-137.
24. Johnson MI, Robinson MC, Marsh C, Robson CN, Neal DE, Hamdy FC,. Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: Relationship with apoptosis and proliferation. Prostate 1998; 37 (4): 223-229.
25. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP,. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4 (7): 844-847.
26. Nocito A, Kononen J, Kallioniemi OP, Sauter G,. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001; 94 (1): 1-5.
27. Merseburger AS, Kuczyk MA, Serth J, Bokemeyer C, Young DY, Sun L, Connelly RR, McLeod DG, Mostofi FK, Srivastava SK, Stenzl A, Moul JW, Sesterhenn IA,. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep 2003; 10 (1): 223-228.